A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study

Bin Liu, Jia-Yi Qian, Lei-Lei Wu, Jun-Quan Zeng, Shu-Quan Xu, Jin-Hua Yuan, Yong-Liang Zheng, Dong Xie* and Hai-Hong Yu*

Objective: The prognostic effect of delayed treatment on stage IA1 non-small cell lung cancer (NSCLC) patients is still unclear. This study aimed to explore the association between the waiting time before treatment and the prognosis in stage IA1 NSCLC patients.

Methods: Eligible patients diagnosed with pathological stage IA1 NSCLC were included in this study. The clinical endpoints were overall survival (OS) and cancer-specific survival (CSS). The Kaplan-Meier method, the Log-rank test, univariable, and multivariable Cox regression analyses were used in this study. Propensity score matching was used to reduce the bias of data distribution.

Results: There were eligible 957 patients in the study. The length of waiting time before treatment stratified the survival in patients [<3 months vs. ≥3-months, unadjusted hazard ratio (HR) = 0.481, P = 0.007; <2 months vs. ≥2-months, unadjusted HR = 0.564, P = 0.006; <1 month vs. ≥1-month, unadjusted HR = 0.537, P = 0.001]. The 5-year CSS rates were 95.0% and 77.0% in patients of waiting time within 3 months and over 3 months, respectively. After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.

Conclusions: A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. We propose that the waiting time for those patients preferably is less than one month and should not exceed two months.

Keywords: non-small cell lung cancer, stage IA1, delayed treatment, prognosis, surgery
Introduction

Lung cancer still has the first mortality among all malignancies, although, its incidence rate had decreased from the first rank to the second rank worldwide (1). The overall survival (OS) of lung cancer has improved due to the development of therapeutic approaches, such as third-generation targeted therapy and anti-PD-1 therapy (2, 3). However, previous studies confirmed that many factors affecting the prognosis led to the low OS rate (4–7). The waiting time from diagnosis to treatment, as a predictive factor for survival before treatment, were studied in some research. However, the conclusions from those studies were inconsistent. Some research suggested that a long waiting time from diagnosis to treatment could decrease the survival outcomes (8, 9), though other studies concluded that delay treatment did not affect the prognosis of patients significantly (10, 11). Thus, there is always a need to investigate the prognostic effect of a long waiting time before treatment on non-small cell lung cancer (NSCLC) patients.

With the popularization of computed tomography and radiomics, the rate of early diagnosis in NSCLC has increased (12, 13). Besides, the percentage of stage I NSCLC diagnosed has increased over the years (14). However, the survival of stage I presented heterogeneity according to the different clinical-pathological features (15, 16). In addition, in the current Covid-19 pandemic, overburdened medical services lead to a long waiting time before treatment (17). Nevertheless, the survival effect of a long waiting time before treatment on NSCLC patients with stage IA1 is unclear. Therefore, this study aimed to explore the maximum waiting time before therapy and its impact on survival outcomes of stage IA1 NSCLC patients and to provide reference information in the clinical practice.

Patients and methods

Patients

This study includes all patients who were diagnosed with a histologically confirmed non-small cell during January 2004 to December 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Histology and site of disease were coded in SEER according to the International Classification of Diseases (ICD) for Oncology, Edition 3 (ICD-O-3). Patients who met the following criteria were enrolled in the study: (1) patients diagnosed as non-small cell lung cancer age ≥18 years old; (2) systemic assess tumor, node, and metastasis (TNM) staged at T1aN0M0 and pathologically confirmed tumor size was smaller than 1.1 cm; (3) patients had only one primary lesion. All patients were excluded if they were found the standard: (1) patients dead within 1 month after diagnosis; (2) patients lost follow-up within 60 months; (3) patients’ waiting time from diagnosis to treatment was unknow. The detailed information about selection standards are shown in Figure 1. Eventually, the study collected the information on 957 patients.

Follow-up

The collected patients have a clear survival time and survival status. We regarded OS and cancer-specific survival (CSS) as observation endpoints. The CSS was from the date of diagnosis to the time of death caused by NSCLC, and the OS was from the date of diagnosis to the time of death. The survival time ranged from 1.0 to 154.0 months, with an average of 73.3 months.

Statistical analysis

Statistical analysis was performed using SPSS Statistics 25.0 software (IBM SPSS, Inc., Chicago, IL, USA), R version 3.5.2 and GraphPad Prism 8. Univariable and multivariable Cox regression analyses were performed to calculate the hazard ratio (HR) and 95% confidence interval (CI) of the variables for overall survival and cancer-specific mortality. Those factors included sex, age, race, marital status, tumor location, surgical approach, chemotherapy, radiotherapy, grade, histological type and waiting time before treatment. A P value <0.05 was considered to be statistically significant. Survival curves were displayed using Kaplan-Meier curves and compared using the log-rank test. A multivariable proportional hazards model regression model was used to
determine the association between treatment waiting time with other clinical features. Propensity score matching (PSM) was used to reduce the bias of data distribution. Statistical tests were based on a two-sided significance level.

Results

Patient characteristics

The clinical characteristics of patients in the study cohort are listed in Table 1. A total of 957 patients entered the analyses. Among these patients, females outnumbered males, constituting 64.8% of the patients. 436 (45.6%) patients were age 65 and below while 521 (54.4%) were over 65 years old. The majority of patients received surgical treatment, with limited resection accounting for 42.6% and lobectomy for 55.3%. Among the degree of tumor differentiation, there were 370 (38.7%) well differentiated, 294 (30.7%) of moderately differentiated, 177 (19.9%) of poor-undifferentiated, and a considerable part of tumor differentiation (N = 116, 12.1%) was unknown. In terms of tumor histological type, there were 564 (58.9%) patients with adenocarcinoma, 164 (17.1%) patients with squamous cell carcinoma, and 229 (23.9%) patients with unknown classification. Given the early stage of the tumor, more than 90% of patients undergo radiotherapy and only about 1.6% were treated with chemotherapy. More than half of patients waited less than 1 month to reach 56.7% (N = 543), and the proportion of patients who received surgery within 2 and 3 months were 79.4% and 91.6%, respectively.

The independence test of propensity score matching dataset

We used PSM analysis to minimize the effect of waiting time within 3 months, whether the sex, age, histological type, tumor grade, surgical approach, to receive radiation or chemotherapy, race, marital status, laterality and location on OS or CSS. In the propensity scored-matched dataset, there were 78 pairs of patients, we found that P value of χ2 test or Fisher exact test after matching had no different from primary dataset (Supplementary Table S1).

Univariable and multivariable analyses

Univariable Cox regression analysis was firstly performed to distinguish prognostic factors, and a total of 12 variables were included. The laterality and location of tumor distribution had no significant impact on overall mortality and cancer-specific mortality (Tables 2, 3). Excluding confounding factors, SCC, squamous cell carcinoma.
| Variable                      | Univariable analysis | Multivariable analysis |
|-------------------------------|----------------------|------------------------|
|                              | HR       | 95% CI | P-value | HR       | 95% CI | P-value |
| Sex                           |          |        |         |          |        |         |
| Male                          | 1        | reference | 1       | reference |         |         |
| Female                        | 0.678    | 0.537–0.855 | 0.001 | 0.684    | 0.534–0.876 | 0.003 |
| Age (years)                   |          |        |         |          |        |         |
| <66                           | 1        | reference | 1       | reference |         |         |
| >65                           | 1.694    | 1.330–2.157 | <0.001 | 1.486    | 1.157–1.909 | 0.002 |
| Histological types            |          |        |         |          |        |         |
| Adenocarcinoma                | 1        | reference | 1       | reference |         |         |
| SCC                           | 2.613    | 1.999–3.416 | <0.001 | 1.546    | 1.152–2.075 | 0.004 |
| Other/unknown                 | 1.103    | 0.818–1.486 | 0.521 | 1.119    | 0.818–1.531 | 0.482 |
| Grade                         |          |        |         |          |        |         |
| Well                          | 1        | reference | 1       | reference |         |         |
| Moderate                      | 2.302    | 1.689–3.139 | <0.001 | 1.880    | 1.352–2.614 | <0.001 |
| Poor-undifferentiated         | 3.340    | 2.421–4.607 | <0.001 | 2.211    | 1.564–3.128 | <0.001 |
| Unknown                       | 1.808    | 1.194–2.738 | 0.005 | 1.363    | 0.882–2.108 | 0.164 |
| Surgical Approach             |          |        |         |          |        |         |
| None                          | 1        | reference | 1       | reference |         |         |
| Limited resection             | 0.154    | 0.095–0.251 | <0.001 | 0.411    | 0.204–0.830 | 0.013 |
| Lobectomy                     | 0.130    | 0.08–0.211 | <0.001 | 0.354    | 0.174–0.723 | 0.004 |
| Chemotherapy                  |          |        |         |          |        |         |
| No                            | 1        | reference | 1       | reference |         |         |
| Yes                           | 3.452    | 1.836–6.492 | <0.001 | 1.742    | 0.891–3.405 | 0.105 |
| Radiotherapy                  |          |        |         |          |        |         |
| No                            | 1        | reference | 1       | reference |         |         |
| Yes                           | 4.599    | 3.022–6.997 | <0.001 | 2.167    | 1.183–3.968 | 0.012 |
| Race                          |          |        |         |          |        |         |
| Caucasians                    | 1        | reference | 1       | reference |         |         |
| Other/unknown                 | 0.528    | 0.353–0.790 | 0.002 | 0.566    | 0.375–0.852 | 0.0006 |
| Waiting time within 3 months  |          |        |         |          |        |         |
| No                            | 1        | reference | 1       | reference |         |         |
| Yes                           | 0.597    | 0.419–0.851 | 0.004 | 0.632    | 0.441–0.906 | 0.013 |
| Marital status                |          |        |         |          |        |         |
| None                          | 1        | reference | 1       | reference |         |         |
| Married                       | 0.723    | 0.571–0.914 | 0.007 | 0.833    | 0.649–1.069 | 0.150 |
| Unknown                       | 0.945    | 0.511–1.747 | 0.856 | 1.402    | 0.749–2.623 | 0.291 |
| Laterality                    |          |        |         |          |        |         |
| Left                          | 1        | reference | 1       | reference |         |         |
| Right                         | 0.934    | 0.738–1.183 | 0.573 |         |         |         |
| Location                      |          |        |         |          |        |         |
| Upper                         | 1        | reference | 1       | reference |         |         |
| Lower                         | 0.899    | 0.697–1.159 | 0.410 |         |         |         |
| Other/unknown                 | 0.642    | 0.408–1.009 | 0.055 |         |         |         |

HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.

Variable with P-value <0.05 in univariable analysis was incorporated in multivariable analysis.

The method of Cox regression was “Enter selection.”
|                          | Univariable analysis | Multivariable analysis |
|--------------------------|----------------------|------------------------|
|                          | HR   | 95%Cl | P-value | HR   | 95%Cl | P-value |
| **Sex**                  |      |       |         |      |       |         |
| Male                     | 1    | reference | 1 reference |
| Female                   | 0.808 | 0.549–1.189 | 0.280 | 0.873 | 0.586–1.300 | 0.503 |
| **Age (years)**          |      |       |         |      |       |         |
| <66                      | 1    | reference | 1 reference |
| >65                      | 1.828 | 1.226–2.725 | 0.003 | 1.565 | 1.036–2.364 | 0.033 |
| **Histological types**   |      |       |         |      |       |         |
| Adenocarcinoma           | 1    | reference | 1 reference |
| SCC                      | 2.099 | 1.753–4.154 | <0.001 | 1.366 | 0.860–2.171 | 0.187 |
| Other/unknown            | 1.041 | 0.633–1.712 | 0.874 | 1.051 | 0.624–1.770 | 0.852 |
| **Grade**                |      |       |         |      |       |         |
| Well                     | 1    | reference | 1 reference |
| Moderate                 | 3.599 | 2.015–6.428 | <0.001 | 3.126 | 1.714–5.701 | <0.001 |
| Poor-undifferentiated    | 5.779 | 3.213–10.39 | <0.001 | 3.869 | 2.093–7.151 | <0.001 |
| Unknown                  | 3.471 | 1.736–6.941 | <0.001 | 2.391 | 1.153–4.958 | 0.019 |
| **Surgical Approach**    |      |       |         |      |       |         |
| None                     | 1    | reference | 1 reference |
| Limited resection        | 0.093 | 0.048–0.183 | <0.001 | 0.396 | 0.167–0.938 | 0.035 |
| Lobectomy                | 0.084 | 0.044–0.163 | <0.001 | 0.378 | 0.158–0.904 | 0.029 |
| **Chemotherapy**         |      |       |         |      |       |         |
| No                       | 1    | reference | 1 reference |
| Yes                      | 8.696 | 4.388–17.24 | <0.001 | 4.101 | 1.953–8.611 | <0.001 |
| **Radiotherapy**         |      |       |         |      |       |         |
| No                       | 1    | reference | 1 reference |
| Yes                      | 8.104 | 4.682–14.03 | <0.001 | 3.170 | 1.537–6.538 | 0.002 |
| **Race**                 |      |       |         |      |       |         |
| Caucasians               | 1    | reference | 1 reference |
| Other/unknown            | 0.368 | 0.171–0.792 | 0.011 | 0.413 | 0.191–0.893 | 0.025 |
| **Waiting time within 3 months** |      |       |         |      |       |         |
| No                       | 1    | reference | 1 reference |
| Yes                      | 0.481 | 0.283–0.818 | 0.007 | 0.474 | 0.276–0.815 | 0.007 |
| **Marital status**       |      |       |         |      |       |         |
| None                     | 1    | reference | 1 reference |
| Married                  | 0.760 | 0.518–1.114 | 0.159 |
| Unknown                  | 0.945 | 0.341–2.615 | 0.913 |
| **Laterality**           |      |       |         |      |       |         |
| Left                     | 1    | reference | 1 reference |
| Right                    | 0.918 | 0.625–1.347 | 0.661 |
| **Location**             |      |       |         |      |       |         |
| Upper                    | 1    | reference | 1 reference |
| Lower                    | 1.088 | 0.731–1.618 | 0.678 |
| Other/unknown            | 0.425 | 0.171–1.054 | 0.065 |

HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.
Variable with P-value <0.05 in univariable analysis or sex was incorporated in multivariable analysis.
The method of Cox regression was "Enter selection".
multivariable analysis confirmed sex, age, SCC, high grade, received surgery, radiotherapy, race and waiting time within 3 months were independent prognostic factors for OS (all \( P < 0.05 \), Table 2). Age, high grade, received surgery, chemotherapy, radiotherapy, race and waiting time within 3 months were independent prognostic factors for CSS (Table 3), a little bit distinguished from OS. Further subdivided the waiting time for surgery, and multivariable analysis showed waiting time within 2 months was independent prognostic factors for CSS (HR = 0.623, 95% CI, 0.409–0.949, \( P = 0.027 \), Table 4).

Prognostic significance of treatment-waiting time

Upon the results of univariable and multivariable analyses, waiting time for treatment within 3 months was a significant prognostic factor in this cohort. The 5-year OS rate was 63.0% and the 5-year CSS rate reached 85.0% in this cohort. The 5-year OS rates of patients with whose waiting time within 3 months or beyond 3 months were 65.0% and 48.0%, respectively (OS: unadjusted HR = 0.597, 95% CI, 0.419–0.851, \( P = 0.004 \), Figure 2A). For CSS rate stratified by treatment waiting time, those whose waiting time within 3 months had a better survival than those with waiting time beyond 3 months (unadjusted HR = 0.481, 95% CI, 0.282–0.818, \( P = 0.007 \), Figure 2B). Although factors such as age, sex, and tumor grade did not influence, we used 78 pairs of patients after PSM for survival analysis. After removing possible underlying factors, we could see patients with waiting time within 3 months had a better survival than those with waiting time beyond 3 months (unadjusted HR = 0.368, 95% CI, 0.200–0.680, \( P = 0.001 \), Figure 2C; CSS: PSM-adjusted HR = 0.374, 95% CI, 0.152–0.919, \( P = 0.026 \), Figure 2D).

The cutoff value of waiting time was further subdivided into within one month and two months, comparing the prognostic level was compared between the two groups. OS rate based on waiting time within one month compared with over one month had no difference (unadjusted HR = 0.831, 95% CI, 0.660–1.047, \( P = 0.117 \), Figure 3A). As for CSS rate, cases with waiting time within one month had more satisfactory outcomes than those with waiting time over one month (unadjusted HR = 0.537, 95% CI, 0.367–0.785, \( P = 0.001 \), Figure 3B). Besides, patients with waiting time within two months had a better survival than those with waiting time over two months (OS: unadjusted HR = 0.726, 95% CI, 0.557–0.946, \( P = 0.018 \), Figure 3C; CSS: unadjusted HR = 0.564, 95% CI, 0.375–0.849, \( P = 0.006 \), Figure 3D).

Discussion

In this study, we used the data of 957 patients to investigate the prognostic impact of a long waiting time before treatment on stage IA1 NSCLC patients. The Kaplan-Meier method was used to compare the significance of different waiting times in the stage IA1 NSCLC patients. The results generated from the analysis of the Kaplan-Meier method showed that waiting time before treatment over one month decreased CSS rates in stage IA1 patients. However, the OS rates were only reduced when the waiting time was longer than two months for the same cohort. Furthermore, univariable and multivariable Cox regression analyses were conducted to identify the overall mortality and cancer-specific mortality. As previous studies presented, females accounted for a higher percentage of early-stage NSCLC than males (16, 18). Besides, the most part of histological type was adenocarcinoma in the small-sized NSCLC (16). Patients with adenocarcinoma had much better survival than cases with squamous cell carcinoma (16, 19). Our study showed the same results as those studies.

In this cohort with tumor size \( \leq 1.0 \) cm, over 90% of patients received surgical resection. Therefore, the 5-year CSS rate reached 85%. We found that waiting time within one month, two months, or three months could improve the prognosis of NSCLC patients with stage IA1 after univariable analysis, although the prognosis of this cohort was satisfactory. After adjusting for other confounders, only patients could significantly get survival benefit whose waiting time was shorter than three months before treatment. Interestingly, the CSS rates could be increased when the waiting time was shorter than two months in the multivariable Cox regression model. Besides, the \( P \)-value of 0.066 was closed to 0.05 in the multivariable analysis when the cut-off point of waiting time was one month. These results might suggest that the waiting time from diagnosis to treatment mainly affected CSS of stage IA1 patients. Therefore, we propose that the waiting time for NSCLC patients with stage IA1 from diagnosis to treatment preferably is less than one month and should not exceed two months.

| TABLE 4 Multivariable Cox regression for patients’ mortality based on different cut-off points of waiting time. |
|---------------------------------|---------------------------------|
|                                 | Overall mortality               | Cancer-specific mortality      |
|                                 | HR     | 95%CI   | P-value | HR     | 95%CI   | P-value |
| Waiting time within 1 month     |        |        |         |        |        |         |
| No                              | 1      | reference | 1 | reference | 1 | reference |
| Yes                             | 1.024  | 0.800–1.310 | 0.852 | 0.684 | 0.457–1.026 | 0.066 |
| Waiting time within 2 months    |        |        |         |        |        |         |
| No                              | 1      | reference | 1 | reference | 1 | reference |
| Yes                             | 0.792  | 0.604–1.039 | 0.092 | 0.623 | 0.409–0.949 | 0.027 |

HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma. Variable with \( P \)-value \(< 0.05 \) in univariable analysis, sex, or age was incorporated in multivariable analysis. The method of Cox regression was ‘Enter selection’. 
There is a long-standing discussion of the impact of waiting time from diagnosis to treatment on patient prognosis. The study results from Diaconescu R et al. showed that the shorter waiting time was associated with shorter survival time (20). However, they only analyzed the data of 495 patients in one cancer center. A recent report from Klarenbeek SE et al. based on a nationwide observational cohort study presented that a more rapid start of therapy did not improve survival outcomes in NSCLC patients with advanced stage (10). The abovementioned research mainly collected NSCLC patients with clinical stage III-IV, though its sample size was large. With the popularization of computed tomography and the development of radiomics, the rate of early diagnosis in NSCLC has increased (12, 13). Some researchers have paid attention to the study of the association between waiting time before therapy and patient survival. Two studies from The United States and South Korea confirmed that a long waiting time before treatment could have a survival effect on early-stage NSCLC patients (9, 21). Besides, delayed treatment was considered mainly affect the long-term mortality rather than short-term survival, such as 5-year mortality (9). However, the above two studies did not classify the detailed groups according to tumor size in cohort with stage I. In the present study, we focused on small-size NSCLC patients and analyzed the data of tumor size ≤1.0 cm. Based on the different observational endpoints (overall mortality and cancer-specific survival), there is a positive correlation between waiting time and survival outcomes. However, the results are not statistically significant. The sample size and the limited follow-up time are the main reasons for this phenomenon. In the future, we will further expand the sample size and improve the follow-up time to verify the relationship between waiting time and survival outcomes.
mortality), different cut-off values of waiting time had a different effect on the prognosis of stage IA1 NSCLC patients. Finally, we suggest that patients receive treatment early in clinical practice.

The effect of delayed treatment on the survival of NSCLC patients was inconsistent (8–10, 20, 21). There are two main reasons for this phenomenon. On the one hand, the cohort from different studies had different treatment approaches due to the different proportions of combined stages. Some patients received timely therapy; perhaps the emergency treatment was due to the urgency of the condition. Therefore, the poorer prognosis of such patients should be due to the condition itself and not to the length of waiting time before therapy (10). On the other hand, some patients did not receive complete essential checks, although those patients underwent timely treatment. However, the treatment received was not optimal for this patient before the detailed diagnosis. Regrettably, the studies mentioned above did not solve those problems. Thus, we still need a prospective study that may be able to explore these questions better.

With the pandemic of Covid-19, the carrying capacity of healthcare systems is being challenged worldwide (22, 23). It is difficult for some patients to receive therapy early (24). Previous studies confirmed that greater psychological distress was associated with slower time to treatment in oncological patients (25, 26). Besides, the psychological burden negatively

![Image of survival curves](image_url)

**FIGURE 3**
The survival curves based on waiting time within one month for overall survival (A) and cancer-specific survival (B), or waiting time within two months for overall survival (C) and cancer-specific survival (D).
influenced survival quality and prognosis in patients with malignant tumors (27, 28). Our findings showed that the waiting time ≥3 months had a significant negative effect on CSS and OS for stage IA1 NSCLC patients after adjusting for other confounders, and the waiting time ≥2 months only influenced OS rates. Although, in general, it is essential to start treatment as early as possible, the present study found that delayed treatment within a limited time might be acceptable. This finding is likely to relieve the patient’s psychological burden and help the doctor to arrange the patient’s treatment appropriately.

There are some drawbacks in the present study. First, the detailed information about waiting days was not obtain from SEER database; therefore, we only analyzed waiting time based on unit of month. Second, the radiological features (such as consolidation-to-tumor ratio) of small-sized tumor were unknown in the lung. Thus, further analysis of small nodules, such as the classification of ground glass nodules or solid nodules, cannot be performed. Third, the selection bias is inevitable, since this study belongs to a retrospective study. Fourth, the information on driver genes and pathological features (such as epidermal growth factor receptor and vascular-lymphatic invasion) was not detailed in the SEER database. Therefore, the detailed data from our hospital was needed to further analysis in the next study. Finally, we need reproducible studies to confirm our findings.

Conclusions

A long waiting time from diagnosis to treatment may decrease the survival of stage IA1 NSCLC patients. We propose that the waiting time for NSCLC patients with stage IA1 before therapy preferably is less than one month and should not exceed two months.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by This study was approved by the Ethics Committee of The Affiliated Hospital of Jinggangshan University. The ethics committee waived the requirement of written informed consent for participation.

Author contributions

Study design: BL, HHY, LLW and XC Data collection: DX, JQZ, SQX, J, HY, YLZ, BL, HHY, LLW and XC Data analyses: JQZ, SQX, J, HY, YLZ, BL, HHY, LLW and XC Data interpretation: BL, HHY, LLW and XC Manuscript drafting: JYQ, LLW and XC. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by Shanghai ShenKang Hospital Development Centre (grant number SHDC22020218), and Science and Technology Plan Project of Jiangxi Provincial Education Department (grant number GJJ170648).

Acknowledgments

We thank all staff from Surveillance, Epidemiology, and End Results.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: http://www.frontiersin.org/articles/10.3389/fsurg.2022.987075/full#supplementary-material.
References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. (2021) 71(1):3-33. doi: 10.3322/caac.21654

2. Wu YL, Tsukoi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. (2020) 383(18):1711-23. doi: 10.1056/NEJMoa2007701

3. Gadgeel S, Rodriguez-Abrue D, Speranza G, Esteban E, Felip E, Dümme M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. (2020) 38(14):1505-15. doi: 10.1200/JCO.19.03136

4. Wu L-L, Li C-W, Li K, Qu L-H, Xu S-Q, Lin W-K, et al. The difference and significance of parietal pleura invasion and rib invasion in pathological T classification with non-small cell lung cancer. Front Oncol. (2022) 12:878482. doi: 10.3389/fonc.2021.878482

5. Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Kocyzywas M, et al. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: the importance of pathological response and lymph node ratio. Lung Cancer. (2019) 133:136–43. doi: 10.1016/j.lungcan.2019.05.020

6. Arrieta O, Salas AA, Cardona AF, Diaz-Garcia D, Lara-Mejia L, Escamilla I, et al. Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. Lung Cancer. (2021) 155:183–90. doi: 10.1016/j.lungcan.2021.01.023

7. Wu LL, Chen WT, Liu X, Jiang WM, Huang YY, Lin P, et al. A nomogram to predict long-term survival outcomes of patients who undergo pneumonectomy for non-small cell lung cancer with stage I-IIIIB. Front Surg. (2021) 8:604880. doi: 10.3389/fsurg.2021.604880

8. Goméz DR, Liao KP, Swisher SG, Blumensohn GR, Erasmus Jr. JF, Buchholz TA, et al. Time to treatment as a quality metric in lung cancer: staging studies, time to treatment, and patient survival. Radiother Oncol. (2015) 115(2):257–63. doi: 10.1016/j.radonc.2015.04.010

9. Han KT, Kim W, Song A, Ju YJ, Choi DW, Kim S. Is time-to-treatment associated with higher mortality in Korean elderly lung cancer patients? Health Policy. (2021) 125(8):1047–53. doi: 10.1016/j.healthpol.2021.06.004

10. Klarenbeek SE, Aerts MJ, van den Heuvel MM, Prokop M, Timmers M, Schuurbers OCI. Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study. Thorax. (2022) thoraxdoi:10.1136/thoraxjnl-2021-218059

11. Stokstad T, Sorhaug S, Amundsen T, Gronberg BH. Associations between time to treatment start and survival in patients with lung cancer. Int J Cancer. (2021) 35(3):1395–403. doi: 10.21873/ijnvivo.121416

12. Wilson R, Devaraj A. Radiomics of pulmonary nodules and lung cancer. Transl Lung Cancer Res. (2017) 6(1):86–91. doi: 10.21037/tlcr.2017.01.04

13. Pinsky MF, Miller E. Use and outcomes of low-dose CT lung cancer screening in the medicare population. Chest. (2022) 50012-3692(202200575-X). doi: 10.1016/j.chest.2022.03.031

14. Potter AL, Rosenstein AL, Kiang MV, Shah SA, Gaisser HA, Chang DC, et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. BMJ. (2022) 376:e69008. doi: 10.1136/bmj-2021-069008

15. Qian F, Yang W, Wang R, Xu J, Wang S, Zhang Y, et al. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. J Thorac Cardiovasc Surg. (2018) 155(3):1227–35. e1222. doi: 10.1016/j.jtcvs.2017.09.143

16. Wu LL, Lai J, Liu X, Huang YY, Lin P, Long H, et al. Association between number of dissected lymph nodes and survival in stage IA non-small cell lung cancer: a propensity score matching analysis. World J Surg Oncol. (2020) 18(1):322. doi: 10.1186/s12957-020-02090-5

17. Dogelé K, Baxter NN, Emery J, Jenkins MA, Franchini F, Gibbs P, et al. An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. Asia Pac J Clin Oncol. (2021) 17(4):359–67. doi: 10.1111/ajco.13505

18. Xi J, Yin J, Liang J, Zhan C, Jiang W, Lin Z, et al. Prognostic impact of radiological consolidation tumor ratio in clinical stage IA pulmonary ground glass opacities. Front Oncol. (2021) 11:66149. doi: 10.3389/fonc.2021.66149

19. Dalwadi SM, Lewis GD, Bernicker EH, Butler EB, Teh BS, Farach AM. Disparities in the treatment and outcome of stage I non-small-cell lung cancer in the 21st century. Clin Lung Cancer. (2019) 20(3):194–208. doi: 10.1016/j.cllc.2018.11.004

20. Diaconescu R, Lafond C, Whitton R. Treatment delays in non-small cell lung cancer and their prognostic implications. J Thorac Oncol. (2011) 6(7):1254–9. doi: 10.1097/JTO.0b013e318217b623

21. Cushman TR, Jones B, Akhavan D, Rushhoven CG, Verma V, Salgia R, et al. The effects of time to treatment initiation for patients with non-small-cell lung cancer in the United States. Cln Lung Cancer. (2021) 22(1):e84–97. doi: 10.1016/j.clincancer.2020.09.004

22. Ferrara P, Albano L. COVID-19 and healthcare systems: what should we do next? Public Health. (2020) 185:1–2. doi: 10.1016/j.puhe.2020.05.014

23. Sun S, Xie Z, Yu K, Jiang B, Zhang S, Pan X. COVID-19 and healthcare system in China: challenges and progression for a sustainable future. Global Health. (2021) 17:114. doi: 10.1097/JTO.0b013e318292d-021-00665-9

24. Torzilli G, Viganò L, Galvani J, Castoro C, Quaglìuolo V, Spinelli A, et al. A snapshot of elective oncological surgery in Italy during COVID-19 emergency: pearls, pitfalls, and perspectives. Ann Surg. (2020) 272(2):e12–7. doi: 10.1097/SLA.0000000000004081

25. Madhusudhana S, Gates M, Singh D, Grover P, Indaram M, Cheng A-L. Impact of psychological distress on treatment timeliness in oncology patients at a safety-net hospital. J Natl Compr Canc Netw. (2022) jncn20058. doi: 10.6004/jnccn.2022.0058

26. Robertson R, Campbell NC, Smith S, Donnan PT, Sullivan F, Duffy R, et al. Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer. (2004) 90(8):1479–85. doi: 10.1038/sj.bjc.6601753

27. Charles C, Bardet A, Larive A, Gorwood P, Ramoz N, Thomas E, et al. Characterization of depressive symptoms trajectories after breast cancer diagnosis in women in France. JAMA Netw Open. (2022) 5(4):e225118. doi: 10.1001/jamanetworkopen.2022.5118

28. Davis NE, Hue JJ, Kyasaram RK, Elshami M, Graor HJ, Zarei M, et al. Prognostic significance of postoperative depression and anxiety among patients with pancreatic cancer. Psychooncology. (2022) 31(8):1390–8. doi: 10.1002/pon.5945